Abstract
Abstract. In a cross‐over design study, 15 healthy young volunteers were randomly allocated an oral contraceptive containing 30 μg EE. Preparation A contained in addition 150 μg of a new progestogenic compound, desogestrel, and preparation B 150 μg levonorgestrel. Subjective side effects were few during use of any of the preparations.Preparations A and B induced similar changes in most of the serum lipid and lipoprotein‐lipid parameters. Body weight, triglycerides, VLDL‐triglycerides and LDL‐free cholesterol, total cholesterol and triglycerides were significantly lower and HDL‐total cholesterol and triglycerides significantly higher with preparation A than preparation B.The relative fatty acid composition of lecithin revealed with preparation B (as compared with preparation A), higher levels of palmitic and linoleic acids which could be interpreted as an enhancement of pathway I for liver lecithin synthesis which in turn is usually coupled to a reduced capacity of liver excretory function.The present data regarding preparation B are in agreement with those reported by others, while preparation A has not been studied before. The differences observed between preparation A and B are ascribed to the more marked androgen‐like effects of preparation B.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
